NCT/Study#

NCT02956382 /

PRO2016-0014-C103287

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

DISEASE GROUP:
Lymphoma
current phase:
Phase I/II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: